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Abstract
Background: Topoisomerase I (Top1) is the target of Top1 inhibitor chemotherapy. The TOP1 gene, located at 20q12-q13.1,
is frequently detected at elevated copy numbers in colorectal cancer (CRC). The present study explores the mechanism,
frequency and prognostic impact of TOP1 gene aberrations in stage III CRC and how these can be detected by fluorescent in
situ hybridization (FISH).
Methods: Nine CRC cell line metaphase spreads were analyzed by FISH with a TOP1 probe in combination with a reference
probe covering either the centromeric region of chromosome 20 (CEN-20) or chromosome 2 (CEN-2). Tissue sections from
154 chemonaive stage III CRC patients, previously studied with TOP1/CEN-20, were analyzed with TOP1/CEN-2. Relationships
between biomarker status and overall survival (OS), time to recurrence (TTR) in CRC and time to local recurrence (LR; rectal
cancer only) were determined.
Results: TOP1 aberrations were observed in four cell line metaphases. In all cell lines CEN-2 was found to reflect
chromosomal ploidy levels and therefore the TOP1/CEN-2 probe combination was selected to identify TOP1 gene gains
(TOP1/CEN-2$1.5). One hundred and three patients (68.2%) had TOP1 gain, of which 15 patients (14.6%) harbored an
amplification (TOP1/CEN-20$2.0). TOP1 gene gain did not have any association with clinical endpoints, whereas TOP1
amplification showed a non-significant trend towards longer TTR (multivariate HR: 0.50, p = 0.08). Once amplified cases were
segregated from other cases of gene gain, non-amplified gene increases (TOP1/CEN-2$1.5 and TOP1/CEN-20,2.0) showed
a trend towards shorter TTR (univariate HR: 1.57, p = 0.07).
Conclusions: TOP1 gene copy number increase occurs frequently in stage III CRC in a mechanism that often includes CEN-
20. Using CEN-2 as a measurement for tumor ploidy levels, we were able to discriminate between different mechanisms of
gene gain, which appeared to differ in prognostic impact. TOP1 FISH guidelines have been updated.
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Introduction
Colorectal cancer (CRC) is a leading cause of cancer death
worldwide. In 2011, CRC accounted for an estimated nine
percent of new cancer cases, as well as nine percent of cancer
deaths in the US [1]. For the treatment of advanced CRC (stage
IV), two chemotherapeutic options are available: 5-Fluorouracil
(5-FU, capecitabine) in combination with irinotecan (FOLFIRI) or
oxaliplatin (FOLFOX) plus biological agents. Several studies
report similar response rates between the two regimens in first line
treatment of advanced disease [2–4], with a single study reporting
a significantly higher response rate with FOLFOX [5]. Interest-
ingly, one of these studies reported a second line 6% objective
response to FOLFIRI treatment following failed FOLFOX and a
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21% objective response to second line FOLFOX treatment
following failed FOLFIRI, indicative of non-complete cross
resistance between irinotecan and oxaliplatin [4]. This finding
raises the question of whether a subset of patients that received
FOLFOX as first line treatment would have benefited from
FOLFIRI as first line treatment, or vice versa. We therefore
consider that efforts directed at the discovery of a predictive
biomarker profile for FOLFOX/FOLFIRI treatment outcome are
warranted.
Irinotecan, a pro-drug of SN-38, functions by inhibiting the
enzyme topoisomerase I (Top1) [6]. Top1 plays an essential role in
alleviating the topological stresses that arise during DNA
replication and transcription by nicking, relaxing and re-ligating
the double-stranded DNA structure. SN-38 binds Top1 and
stabilizes the intermediate DNA-Top1 complexes. Subsequent re-
ligation is inhibited, which ultimately results in cell death due to
DNA damage during DNA replication or transcription [6,7].
Top1 has due to its role as a target for SN-38 been proposed as a
possible predictive biomarker for FOLFIRI treatment outcome. In
advanced colorectal cancer, two large retrospective studies
investigating the relationship between Top1 protein levels and
irinotecan treatment outcome produce conflicting results [8,9].
While these efforts have been directed at studying Top1 protein
levels, research into chromosomal alterations involving the
topoisomerase I gene (symbol: TOP1) are limited. Located at
20q12-q13.1, part of the frequently gained 20q region implicated
in adenoma to carcinoma progression [10–13], TOP1 is found at
elevated copy numbers in a large fraction of stage III CRC
samples when detected by Fluorescent In Situ Hybridization
(FISH) [14,15],
In our study of TOP1, we have previously shown that in a stage
III CRC chemonaive patient cohort (n = 154), increased TOP1
gene copy number was significantly associated with longer survival
(OS) [15]. Interestingly, an estimated 71% of patients harbored a
TOP1 gene copy increase, whereas only 10% of patients harbored
a TOP1 amplification [TOP1/CEN-20 (centromere 20) Ratio
$2.0] [15], indicating that gene amplification is not the most
common mechanism for generating additional copies of TOP1. A
strong correlation between TOP1 and CEN-20 was found,
revealing an association between TOP1 and CEN-20 copy number
increases. This would suggest that gene gain mechanisms involving
both the TOP1 locus and the chromosome 20 centromeric region
also occur, possibly by gain of the whole 20q arm by e.g.
isochromosome formation or whole chromosome 20 gain
(aneusomy). This type of gene copy number increase occurs by
mechanisms related to chromosome missegregation and not gene
amplification. Measuring gene copy number alterations by FISH
traditionally relies on the use of a same chromosome reference
probe, e.g. using CEN-20 for measuring genes on chromosome 20,
we therefore set out to develop a novel FISH assay to distinguish
tumor specimens with TOP1 copy number increases due to
amplifications from those with increases due to 20q gain or
aneusomy by applying a reference probe directed at an unrelated
chromosome.
The purpose of the current study is to determine the frequency
of TOP1 alterations, map any prognostic effects of these gene
aberrations, identify cut-offs that reflect the underlying genetic
mechanisms of TOP1 copy number alterations and update FISH
scoring guidelines to reduce observer workload. To achieve these
goals, the mechanism of TOP1 gene copy gain was investigated in
a panel of CRC cell lines with the aim of identifying a reference
probe that truly reflects ploidy levels, so that TOP1 copy number
increases should be detected in relation to the total number of
chromosomes (ploidy level) and this is best done through the use of
a gene to centromere ratio. A novel probe combination, consisting
of TOP1 and a centromere 2-specific (CEN-2) probe, was then
applied to the previously tested stage III CRC patient samples to
discriminate between patients harboring TOP1 copy number
increases caused by mechanisms involving chromosome misse-
gregation and those caused by gene amplification. The relation-
ship between the different mechanisms of TOP1 copy number
increase and patient prognosis was investigated. Additionally,
based on all FISH data, we could update the TOP1 FISH scoring
guidelines.
Materials and Methods
2.1 Patients and Clinical Material
One hundred fifty-four CRC patients with histologically verified
stage III adenocarcinomas and obtainable FFPE tumor specimens
were selected as previously described (see Fig. 1) [15]. All patients
had surgical resections of their CRC and received no adjuvant
radio- and/or chemotherapy, as this was not part of standard
CRC treatment in Denmark at the time (April 1991-August 1993).
Patients were randomized to receive either Ranitidine or placebo
for up to five years with no effect of ranitidine on survival reported
[16]. Participants provided written informed consent and the study
was conducted in accordance with the Helsinki II Declaration with
approval from the Danish National Board of Health (2760-419-
1989), Data Protection Agency (1991-1110-751) and Central
National Ethics Committee (KF 01-2045/91). The approval
included collection of tissue specimens for subsequent analysis of
biological markers (KF 01-078/93).
2.2 Preparation of Metaphases & Non-truncated
Interphase Nuclei
CRC cell lines Colo-205, HCC-2998, HCT-15, HCT-116, HT-
29, KM12, and SW620 were obtained from the NCI/Develop-
ment Therapeutics Program, while DLD-1, LoVo, and LS-174T
were obtained from the American Tissue Culture Collection. The
Figure 1. CONSORT flow diagram describing the selection
method of samples included in this study.
doi:10.1371/journal.pone.0060613.g001
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cell lines were maintained at 37˚C, 5% CO2 in RPMI 1640
GlutaMAXTM growth medium (Invitrogen, Carlsbad, USA)
supplemented with 10% fetal calf serum (Invitrogen). Once
cultures reached a confluence of ,70%, colcemid (Invitrogen)
was added and cultures were incubated for 2 h at 37˚C.
Subsequently, cells were harvested and a hypotonic treatment
was performed (0.075 M KCl) for 10 min. Fixation was performed
(fixative: 3:1 vol/vol absolute methanol and glacial acetic acid) and
this suspension was dripped onto glass slides.
2.3 TOP1/CEN-2 Probe Mixture
The TOP1 gene probe has previously been described elsewhere
[14]. A CEN-2 specific probe (Dako, Glostrup, Denmark),
consisting of several FITC-labeled peptide nucleic acid monomers
directed at repetitive a-satellite sequences, was combined with the
Texas Red-labeled DNA gene probe in the IQFISH buffer
[17](Dako). The TOP1/CEN-20 probe combination has previ-
ously been described [14].
2.4 FISH Procedure
FISH reagents were from the Cytology FISH Accessory Kit
(K5499) and the Histology FISH Accessory Kit (K5799) (Dako).
Metaphase specimens were fixed in 3.7% formaldehyde, washed,
dehydrated (in a 70%, 85%, 96% ethanol series) and air-dried.
FISH probe was loaded onto slide, denatured at 82uC (TOP1/
CEN-2:5 min, TOP1/CEN-20:10 min) and hybridized (TOP1/
CEN-2:1 h, TOP1/CEN-20: overnight). Excess probe was re-
moved by washing in stringency buffer (TOP1/CEN-2:63uC,
TOP1/CEN-20:65uC). Slides were washed, dehydrated, air dried
and mounted. TOP1/CEN-2 FISH hybridization to FFPE
specimens (thickness: 3 mm) was performed according to the
manufacturer’s recommendations (Dako). Briefly, slides were heat
pretreated (in microwave oven) and pepsin digested at 37uC. Slides
were subsequently denatured at 66uC for 10 min and hybridized
at 45uC for 1–2 h and thereafter treated as described above.
2.4.1 Scoring. FISH signals were initially scored as previously
described [14]. Briefly, signals were counted in 60 relevant non-
overlapping nuclei if signals were, as a minimum, visible at 2006
magnification in the appropriate filter. Scoring was performed at
10006magnification in the Texas Red/FITC double filter. Signal
counts were typed directly into an electronic scoring sheet (kindly
provided by A. Schønau, Dako, Glostrup, Denmark). Initially, 60
nuclei were scored for each specimen following TOP2A FISH
pharmDxTM guidelines (Code K5333, package insert, 1st edition,
2008.01.18) where nuclei harboring both signals, as well as nuclei
harboring only reference signals were scored, which facilitates the
detection of gene deletions. To improve assay sensitivity, only
nuclei harboring both gene- and reference signals were included
for further analysis.
To determine the mechanism of TOP1 copy number increase in
cell lines, signal locations and numbers were noted for 50
metaphases for each cell line. The total number of chromosomes
for each cell line was determined by taking digital images of three
metaphases for each cell line and counting the total number of
chromosomes manually.
To determine the haploid, diploid, triploid and tetraploid
ranges for CEN-2, 60 nuclei were counted in the unaffected
epithelium adjacent to tumor tissue. The diploid range was defined
as follow 2n 2 (n/2) [min] #2n ,2n+(n/2) [max], where 2n
equals the mean CEN-2 counts per nucleus in the (diploid)
unaffected epithelium. The triploid and tetraploid ranges were
found by using 3n or 4n instead of 2n, respectively. The haploid
and high ploidy level ranges were defined as below the diploid
range and above the tetraploid ranges, respectively. Definition of
ploidy ranges has previously been described [18].
2.5 Statistical Methods
All descriptive and survival analyses were performed by use of
SAS 9.2 (SAS Institute, Cary, USA). R version 2.15.1 was used in
scoring method optimization.
2.5.1 Scoring methods. Gene to centromere ratios were
calculated by including either the first 10 or 20 nuclei, determining
TOP1 status and comparing this to the status after inclusion of all
relevant nuclei. Concordance was calculated by use of Kendall’s
tau [tau = (agree-disagree)/(agree+disagree)]. Borderline intervals
near the cut-off values, where additional nuclei must be included
(for 10 nuclei, an additional 10 nuclei had to be scored; for 20
nuclei, an additional 20 nuclei had to be scored) were defined as
greater than or equal to 1.35 (min) and less than 1.65 (max) when
applied cut-off was 1.5. Using HER2/CEN-17 guidelines, the
borderline interval covering the cut-off of 2.0 was defined as
greater than or equal to 1.8 (min) and less than 2.2 (max) [19].
Concordance and mean number of nuclei scored were calculated
with and without borderline intervals.
2.5.2 Survival analysis. Three endpoints were considered:
overall survival (OS, time to death by any cause), time to
recurrence (TTR, time to any event related to colorectal cancer)
and time to local recurrence in rectal cancer (LR) (described in
detail in [15]). Kaplan-Meier estimates of survival probabilities are
presented for the binary variables and some combinations.
Multivariable analysis was done adjusting for gender, age (per
10 year difference in age) and tumor localization (RC versus CC).
Cox regression analysis was used for the analyses. The models
were validated by assessing the proportionality assumption and
linearity for continuous covariates employing Scho¨nfeld and
Martingale residuals. TOP1 and CEN-2 copy numbers, when
analyzed as a continuous variable were log transformed (base 2)
and therefore reflected a two-fold difference for these variates.
Results are presented by hazard ratios (HR) with 95% confidence
intervals (CI) and p-values. All calculated p-values were two-sided
and considered significant at 0.05.
Results
3.1 Mechanisms of TOP1 Gene Copy Increase in Cell Line
Panel
To determine the underlying mechanism(s) of TOP1 gene copy
number increase, metaphase spreads were prepared from a panel
of ten CRC cell lines. Metaphase preparation was successful for all
but one of the cell lines (LS-174T). Following subsequent
hybridization with the TOP1/CEN-20 probe, metaphase spreads
were analyzed with regards to total number of chromosomes, the
number of gene- and centromere-signals, as well as signal location,
the results of which can be viewed in Table 1 and Figure 2. TOP1
gene copy number increases were observed in four of the nine cell
lines. In both Colo-205 and SW620, gene gain appeared to be
linked to chromosome 20 aneusomy (Fig. 2A and 2D, respective-
ly). In HT-29 (Fig. 2B), TOP1 gene gain occurred in a fashion
suggestive of 20q isochromosome formation. In KM12, TOP1 gain
occurred independently of CEN-20 (Fig. 2C). No TOP1 amplifi-
cations were observed. As shown in Table 1, only TOP1 gene gains
which do not involve CEN-20 (in a 1:1 fashion) are reflected in the
TOP1/CEN-20 ratio.
3.2 Identification of a New Reference Probe
To identify a relevant marker for cellular ploidy, i.e. the total
number of chromosomes, the NCI and NCBI’s SKY/M-FISH
TOP1 FISH in Stage III Colorectal Cancer
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and CGH Database (http://www.ncbi.nlm.nih.gov/sky/skyweb.
cgi) was screened. Chromosome 2 appeared to be the least affected
by independent numeric aberrations, such as whole chromosome
gain, and was therefore selected for further analysis in the cell line
metaphase panel. As shown in Table 1, triploid cell lines (Colo-205
and HT-29) were found to produce three CEN-2 signals, while the
diploid cell lines produced only two. All TOP1 gene copy increases
were reflected in the TOP1/CEN-2 ratio using a cut-off value of
1.5, representing a 3:2 situation between gene and centromere and
reflecting an additional TOP1 copy in a diploid cell.
3.3 Stage III CRC Patient Material
TOP1/CEN-2 FISH hybridization and evaluation was success-
ful for 151 of 154 patient FFPE tumor samples (98%) (see Fig. 1).
The distribution of TOP1 and CEN-2 signals was homogeneous in
tumor specimens. To improve upon sensitivity to detect specimens
harboring additional copies of TOP1, only nuclei harboring both
TOP1 and CEN-2 signals were included in subsequent analysis,
which resulted in a median of 58 nuclei scored for each tumor
specimen (range: 47–60). In 50 randomly selected samples, CEN-2
signals were counted in the unaffected colon mucosa to determine
mean signals counts (mean: 1.37, median: 1.38, range: 1.20–1.62).
These counts were used to define the diploid range (see section
2.4.1).
In the tumor material, CEN-2 ranged from 1.19 to 2.52 with a
median of 1.70. By comparing mean CEN-2 signals counts from
the tumor nuclei to the non-tumor nuclei, the majority (97.4%) of
tumor samples could be classified as harboring two (disomic) or
three (trisomic) copies of chromosome 2 (Table 2). In the tumor
samples, TOP1 signals ranged from 1.33 to 6.72 per nucleus with a
median of 3.17 signals while the TOP1/CEN-2 ratio ranged from
1.01 to 3.39 with a median of 1.92. No deletions (TOP1/CEN-
2,0.8) were observed.
3.3.1 Determining TOP1 status. To identify samples
harboring a TOP1 gene copy number increase, a TOP1/CEN-2
ratio cut-off of 1.5 was applied. As shown in Fig. 3, samples
producing ratios equal or above this cut-off received the TOP1
status ‘Gain’, whereas those below were termed ‘TOP1 Normal’.
Initially, 103 patients (68.2%) were classified as ‘Gain’ using this
cut-off.
Once tumor specimens harboring an additional copy of TOP1
were identified, data on TOP1/CEN-20 was used to elucidate the
mechanism of TOP1 gene copy increase. By applying a TOP1/
CEN-20 ratio cut-off of 2.0 to distinguish between samples where
TOP1 gene gain occurs independently of CEN-20 (TOP1/CEN-
20$2.0) from those where gene gain occurs due to aneusomies or
20q isochromosome formation (TOP1/CEN-20,2.0), specimens
with a TOP1 gain could be further dichotomized into amplified
and non-amplified subgroups. Therefore, samples producing a
TOP1/CEN-2 ratio of equal or above 1.5 and a TOP1/CEN-20
ratio above or equal to 2.0 were termed ‘TOP1 Amplification’,
whereas for those below 2.0 were given a ‘TOP1 Non-amplified
Figure 2. Metaphases of CRC cell lines with TOP1 gene copy number increases. A: Colo-205, B: HT-29 (lower right corner: digitally enlarged
isochromosome), C: KM12, D: SW620. Note: Due to the existence of two chromatids in each metaphase chromosome, the observed number of gene
signals is double that of what is observed in an interphase nucleus.
doi:10.1371/journal.pone.0060613.g002
Table 1. CRC cell line stemline populations.
Cell Line
Number of
Chromosomes Ploidy level TOP1 Count CEN-20 Count CEN-2 Counts TOP1/CEN-20 Ratio TOP1/CEN-2 Ratio
Colo-205 71–72 Near Triploid 5 5 3 1.00 1.67
DLD-1 45–47 Near Diploid 2 2 2 1.00 1.00
HCC-2998 46–49 Near Diploid 2 2 2 1.00 1.00
HCT-116 45–48 Near Diploid 2 2 2 1.00 1.00
HCT-15 44–46 Near Diploid 2 2 2 1.00 1.00
HT-29 68–72 Near Triploid 5 4 3 1.25 1.67
KM12 43–44 Near Diploid 3 2 2 1.50 1.50
LoVo 46–47 Near Diploid 2 2 2 1.00 1.00
SW620 43–49 Near Diploid 3 3 2 1.00 1.50
doi:10.1371/journal.pone.0060613.t001
TOP1 FISH in Stage III Colorectal Cancer
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Gain’ status (see Fig. 3). As shown in Table 3, the majority (58.4%)
of tumor specimens received a TOP1 Non-amplified Gain status.
All samples classified as TOP1 Amplification were also found
produce a TOP1/CEN-2 ratio of above 2.0 (see Table 3).
To verify the categorization of samples into subgroups, mean
CEN-2 and CEN-20 signals in tumor nuclei were compared to
their respective means in unaffected colon mucosa, the results of
which are listed in Table 2. Samples with mean CEN-2 and CEN-
20 in the diploid range belonged in 21/34 (61.8%) cases to the
TOP1 Normal category. Near-triploid and CEN-20 aneusomic
cases were most often found in the samples classified as TOP1
Non-amplified Gain. CEN-2 aneusomy was observed in 19
(12.6%) cases.
3.3.2 Association with patient outcome. The relationship
between biomarker status and patient outcome was explored in
both univariate and multivariate models. In this patient cohort,
there were 112 deaths of all causes and 88 recurrences including
cancer-specific deaths within five years [15]. TOP1 copy number,




Whole nuclei CEN-2 copy number/Truncated nuclei
Frequency n
(%a)
Frequency of samples with
CEN-20 aneusomy (CEN-
20.CEN-2)b




Haploid/Monosomy 1 0.69 ,1.03 0 (0) 0 (0) 0 (0)
Diploid/Disomy 2 1.37 [1.03–1.72) 79 (52.3) 45 (29.8) 0 (0)
Triploid/Trisomy 3 2.06 [1.72–2.41) 68 (45.0) 26 (17.2) 17 (11.3)
Tetraploid/Tetrasomy4 2.75 [2.41–3.09) 4 (2.7) 1 (0.7) 2 (1.3)
High ploidy level .5 – $3.09 0 (0) 0 0 (0)
a% denotes the percentage of specimens in category relative to the total number of specimens (151).
bCEN-20 aneusomy was defined as specimens with CEN-20 signals in a higher ploidy range than CEN-2. CEN-2 aneusomy was similarly defined, although vice versa.
doi:10.1371/journal.pone.0060613.t002
Figure 3. Types of TOP1 gene copy number increases by TOP1 status. Red line denotes TOP1 gene signal and green dot denotes centromeric
signal. Examples are based on CRC cell line metaphase results – trisomy (SW620), pentasomy (Colo-205), 20q isochromosome formation (HT-29) and
20q gain (KM12).
doi:10.1371/journal.pone.0060613.g003
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by itself, was not significantly associated with OS, TTR or LR (see
Table 4). Higher CEN-2 copy numbers were associated with
better prognosis with OS as clinical endpoint in the multivariate
analysis (HR: 0.38, 95% CI: 0.15–0.98, p = 0.04), while only a
tendency was observed in the univariate analysis (HR: 0.49, see
Table 4).
Initially, patients harboring TOP1 increases (TOP1 Gain, see
Fig. 3) were compared to those without (TOP1 Normal). Gain of
TOP1 was not significantly associated with OS or TTR in both the
univariate and multivariate analysis (see Table 4). Patients with
TOP1 amplifications (TOP1/CEN-20$2.0) were initially com-
pared to non-amplified cases (TOP1 Normal and TOP1 Non-
amplified Gain subgroups combined). Amplification of TOP1 was
not significantly associated with OS or TTR, although approached
significance for TTR in the multivariate analysis (HR: 0.50, 95%
CI: 0.23–1.09, p = 0.08). Analysis of TOP1 amplifications in
relation to LR failed due to a very limited number of events.
Additional cut-offs for both probe combinations were investigated
and the results are listed in Table 4.
Following the primary analysis of data, specimens were stratified
in subgroups depending on the presence and type of TOP1
increase (see Fig. 3, listed in Table 3). As shown in Table 5, no
significant difference was observed between the TOP1 Normal,
TOP1 Non-amplified Gain and TOP1 Amplification subgroups
with OS as endpoint in both the univariate and multivariate
analysis. With TTR as clinical endpoint, TOP1 non-amplified
gains showed a tendency towards shorter TTR (HR: 1.57, 95%
CI: 0.97–2.55, p = 0.07) in the univariate analysis, and a similar,
but weaker, tendency observed in the multivariate analysis (HR:
1.49). TOP1 amplifications did not exhibit any significant
relationship to TTR when compared to the TOP1 Normal
baseline subgroup. A Kaplan-Meier plot for these relationships
can be viewed in Fig. 4B.
3.4 TOP1 Scoring Guidelines
The possibility of scoring fewer nuclei in the determination of
TOP1 status presents an opportunity to diminish the observer
workload. To determine whether this was possible, status of
TOP1/CEN-2 and TOP1/CEN-20 was determined using 10 or 20
nuclei and compared with the ratio status after the inclusion of all
relevant nuclei. As shown in Table 6, scoring a reduced number of
nuclei, such as only 10 or 20 nuclei to determine TOP1/CEN-2
status (cut-off 1.5) classified samples with moderate concordance
(0.76 and 0.91, respectively), which increased with the introduc-
tion of borderline intervals, where additional nuclei must be scored
(see section 2.5.1). For the detection of TOP1 amplifications (cut-
off: 2.0), concordance was relatively high (10 nuclei: 0.96, 20
nuclei: 0.99) and was not improved with the use of borderline
intervals. Additionally, alternative cut-offs were investigated, the
results of which are listed in Table 6.
Discussion
4.1 Mechanisms of TOP1 Copy Number Increase
In this study, four different mechanisms of TOP1 copy number
increase were identified. In the cell line panel mechanisms
involving TOP1 and CEN-20 (Colo-205, HT29 and SW620) as
well as a mechanism where TOP1 was gained independently of
CEN-20 (KM12), were observed. In Colo-205 and SW620,
Table 3. TOP1 status in 151 CRC samples.
TOP1 Status Cut-Off Values Ratio Range (min-max) Frequency n (%a)
TOP1/CEN-2 TOP1/CEN-20 TOP1/CEN-2 TOP1/CEN-20
Normal ,1.5 – 1.01–1.47 0.99–1.57 48 (31.8)
Non-amplified Gain $1.5 ,2.0 1.52–3.25 0.99–1.87 88 (58.3)
Amplification $1.5 $2.0 2.04–3.39 2.05–2.93 15 (10.0)
a% denotes percentage of samples relative to total number of samples.
doi:10.1371/journal.pone.0060613.t003
Table 4. Biomarker status and association to patient
outcome (measured by three clinical endpoints).
Clinical
Endpoint Variate Univariate Multivariate*
HR 95% CI p-value HR 95% CI p-value
OS TOP1 0.77 0.53 1.13 0.18 0.76 0.51 1.13 0.18
CEN-2 0.49 0.20 1.18 0.11 0.38 0.15 0.94 0.04
TOP1/CEN-
2$1.5
0.93 0.63 1.39 0.73 0.98 0.65 1.47 0.92
TOP1/CEN-
2$2.0
0.85 0.59 1.23 0.39 0.92 0.63 1.34 0.67
TOP1/CEN-
20$1.5
0.92 0.61 1.37 0.67 0.78 0.51 1.18 0.23
TOP1/CEN-
20$2.0
0.60 0.31 1.15 0.13 0.59 0.31 1.14 0.11
TTR TOP1 0.93 0.61 1.42 0.74 0.84 0.54 1.30 0.43
CEN-2 0.55 0.21 1.49 0.24 0.50 0.18 1.39 0.18
TOP1/CEN-
2$1.5
1.40 0.87 2.25 0.17 1.31 0.80 2.14 0.28
TOP1/CEN-
2$2.0
1.09 0.72 1.65 0.69 1.07 0.70 1.63 0.75
TOP1/CEN-
20$1.5
0.87 0.55 1.39 0.57 0.71 0.44 1.15 0.17
TOP1/CEN-
20$2.0
0.54 0.25 1.17 0.12 0.50 0.23 1.09 0.08
LR TOP1 0.62 0.29 1.34 0.22 0.61 0.27 1.39 0.24
CEN-2 0.42 0.08 2.23 0.31 0.32 0.05 2.01 0.22
TOP1/CEN-
2$1.5
1.26 0.48 3.31 0.64 1.40 0.51 3.82 0.51
TOP1/CEN-
2$2.0
0.74 0.36 1.54 0.43 0.77 0.37 1.63 0.50
TOP1/CEN-
20$1.5
0.59 0.27 1.31 0.20 0.56 0.25 1.27 0.17
TOP1/CEN-
20$2.0
NA – – – NA – – –
NA: Not applicable.
*Adjusted for age, gender and tumor localization.
doi:10.1371/journal.pone.0060613.t004
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chromosome 20 aneusomy was observed, in agreement with the
NCI and NCBI’s SKY/M-FISH and CGH Database (http://
www.ncbi.nlm.nih.gov/sky/skyweb.cgi). This type of increase
transpires due to the missegregation of chromosomes during
mitosis, resulting in an abnormal number of chromosomes; a
karyotypic state termed ‘aneuploidy’.
In HT29, TOP1 gain occurred in a manner suggestive of the
formation of an isochromosome, in line with other results [20].
This mechanism of TOP1 gene copy number increase occurs
owing to a misdivision of the centromere (transverse breakage,
rather than longitudinal) during chromosome segregation, result-
ing in a chromosome with two identical arms. In KM12, an
additional TOP1 signal was observed on a chromosome which did
not harbor a CEN-20 signal. In the NCI and NCBI’s SKY/M-
FISH and CGH Database, this cell line appears to harbor a fusion
chromosome of 22q and an additional copy of 20q, where CEN-
20 (or at least the alpha-satellite sequences targeted by the CEN-20
probe) was not gained along with the rest of 20q. This type of gain
may be the product of chromosome 20 aneusomy followed by a
Robertsonian translocation event.
While gene copy number increase can occur due to events
involving larger chromosomal regions, such as the gain of whole
chromosomes or chromosomal arms, it can also occur due to gene
amplification. Gene amplification has been proposed to occur
through several mechanisms, including errors in DNA replication
and repeated breakage-fusion-bridge cycles due to double-strand
DNA break or telomere dysfunction [21–23]. A chromosomal
region preferentially gained through amplification is termed an
‘amplicon’, an approximately 0.5–10 Mb DNA fragment in
length, and usually encompasses gene(s) involved in promoting
tumor growth [24]. It should be noted that whole chromosome or
chromosome arm alterations generally occur more frequently, but
in lower magnitude, than to smaller chromosomal alterations [25].
In the present study, TOP1 gene amplification was defined as
TOP1/CEN-20 ratio equal or above 2.0. This definition means
that TOP1 exists at levels double that of its host chromosome.
Therefore, this type of gene copy increase is probably due to the
copy number increase of an amplicon and not arm-length
chromosomal regions, since its mechanism of copy number
increase is independent of CEN-20. No TOP1 amplifications were
observed in the nine cell lines investigated, but was detected in
10% of tumor samples. This could suggest that either this
mechanism is patient-specific or that this mechanism was not
present in our limited number of cell lines investigated.
Amplification of the TOP1 gene has also been reported in
melanoma [26] and gastric cancer [27].
While each of the aforementioned mechanisms of TOP1 gene
copy number increase occur as single events in cell lines, our
results indicate that they can occur simultaneously in tumor
specimens. In 4/15 (26.7%) cases of amplification (data not
shown), CEN-20 aneusomy was detected, indicative of an
amplification mechanism, as well as one involving aneusomy or
isochromosome formation. In samples classified as TOP1 Non-
amplified Gain, it is possible that both 20q isochromosomes and
additional copies of chromosome 20 are present. However, it is
only possible to classify specimens according to predominant
mechanism.
Table 5. TOP1 Status and association to prognosis.
Clinical Endpoint TOP1 Status Univariate Multivariate*
HR 95% CI p-value HR 95% CI p-value
OS Normal 1.00 – – – 1.00 – – –
Non-amplified Gain 1.01 0.68 1.52 0.95 1.08 0.71 1.64 0.72
Amplification 0.61 0.30 1.22 0.16 0.62 0.31 1.26 0.19
TTR Normal 1.00 – – – 1.00 – – –
Non-amplified Gain 1.57 0.97 2.55 0.07 1.49 0.91 2.46 0.12
Amplification 0.73 0.31 1.70 0.47 0.66 0.28 1.55 0.34
*Adjusted for age, gender and tumor localization.
doi:10.1371/journal.pone.0060613.t005
Figure 4. Kaplan-Meier plots illustrating patient outcome according to TOP1 status. A (left): OS, B (right): TTR.
doi:10.1371/journal.pone.0060613.g004
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4.2 Role of 20q
Gain of chromosome 20 or 20q has been widely reported as a
recurrent chromosomal abnormality in colorectal cancer [11,28–
33], supporting the high frequency of TOP1 non-amplified gains
observed in this study. In vitro models suggest that 20q gain plays
a causative role in tumorigenesis, as well as in increasing cellular
proliferation rates [34]. In colorectal cancer, 20q is believed to
play a role in colorectal adenoma to carcinoma progression [10–
13] and is often observed in tumors exhibiting the microsatellite
stable and/or chromosomal instability phenotypes [32,35,36].
Numerous genes located on 20q have been reported to have
altered expression as a consequence 20q gain, including several
well-known cancer-related genes, such as AURKA (20q13.2) [11],
BCL2L1 (20q11.21) [25] and AIB1 (20q12) [27]. TOP1 mRNA
expression has not been reported to be affected by copy number
increases, whereas PLCG1, a neighboring gene (and partly covered
by the TOP1 FISH probe), copy number increases have been
found to correlate significantly with expression [27]. It should be
noted that PLCG1 appears to be involved in tumorigenesis [37].
4.3 Centromere 2 Versus Centromere 20
Following the analysis of TOP1/CEN-20 in this patient cohort
[15], it became evident that TOP1 underwent copy number
increases in conjunction with CEN-20 in a large fraction of
specimens. Therefore, CEN-20 was deemed to be an inappropri-
ate marker for cellular ploidy levels. In our analysis of the
metaphase cell line panel, CEN-2 was found to correctly reflect the
total number of chromosomes and thus the ploidy levels.
Chromosome 2 has not been reported to undergo above
background numeric aberrations in CRC [11,28–33,35]. In a
landmark study, consisting of 3138 cancer specimens from 26
different cancer types, 2p and 2q were shown to undergo
significantly fewer arm-level alterations when compared to other
chromosomes [25]. Using the Mitelman Database of Chromo-
some Aberrations and Gene Fusions in Cancer (http://cgap.nci.
nih.gov/Chromosomes/Mitelman) to investigate the frequency of
numerical aberrations involving chromosome 2 in tumors of the
large intestine, 55 cases were identified from a total of 524
(consisting of adenomas, adenocarcinomas and carcinomas of the
large intestine), a frequency of 10.3%. Of these 55 cases, 29 would
not result in incorrect TOP1 status; 20 would result in false
negatives; 5 would result in false positives; and a single case not
providing sufficient karyotypic information to determine TOP1
status. Overall, CEN-2 would allow correct TOP1 status
categorization in 95.2% of samples. These findings support the
use of CEN-2 as a reference probe to measure cellular ploidy levels
in tumors of the large intestine.
A comparison of CEN-2 and CEN-20 signals in tumor nuclei
revealed a high frequency of CEN-20 aneusomy (47.6%),
supporting the presence of additional copies of chromosome 20
or 20q. CEN-2 aneusomy was detected in 19 specimens (12.6%). It
should be noted that these findings are merely estimations, as
ploidy ranges were defined by the mean signal counts in unaffected
colon epithelium by two different observers. In normal tissue,
mean CEN-20 was found to be 1.57 [15], whereas CEN-2 was
1.37, a discrepancy that may be attributed to interobserver
variability and illustrates the potential pitfall of using mean signal
counts in the analysis of FISH data.
4.4 Association to Patient Outcome
We have previously reported that higher TOP1 gene copy
numbers, when analyzed as a continuous variable, were associated
with improved patient outcome in this particular patient cohort
[15]. With OS as endpoint, TOP1 increases were previously
reported to be significantly associated with longer survival in both
the univariate (HR: 0.71, 95% CI: 0.50–0.99, p = 0.04) and
multivariate analysis (HR: 0.62, 95% CI: 0.42–0.90, p = 0.01)
[15]; however, these findings could not be reproduced in the
current study. This suggests that the previously reported findings
regarding OS and TTR may have been observer dependent.
The TOP1 Gain status, by itself, was not associated with altered
OS, TTR or LR, which may be due to the inclusion of TOP1
amplified specimens. Once amplified cases were segregated from
cases of TOP1 gain, a trend toward shorter TTR was observed for
TOP1 non-amplified gains (see Table 5). Amplification of the
TOP1 gene, representing a situation where CEN-20 is not involved
in gene gain, exhibited a weak trend towards longer TTR when
compared to the rest of the population, a finding which may be
attributed to the low number of event in this particular subgroup.
When compared only to the TOP1 Normal subgroup, this effect
diminished. While TOP1 Non-amplified gains showed a tendency
towards poor prognosis (with TTR as endpoint), TOP1 amplifi-
cation displayed a weak trend towards better prognosis (with OS as
endpoint), producing non-significant hazard ratios below 1.0 (see
Fig. 4B, table 5). It is unknown what effect the different TOP1 gain
mechanisms have on protein expression and why they may harbor
opposite prognostic impacts. It should be noted that only 15
specimens (10%) were amplified, a low amount for a study of
modest size. This observation requires validation in a larger
patient cohort.
Table 6. Characteristics of the updated scoring guidelines.
Probe Ratio cut-off Borderline interval Concordance Mean number of scored nuclei
10 nuclei 20 nuclei 10 nuclei 20 nuclei
TOP1/CEN-2 1.5 none 0.76 0.91 10 20
1.5 1.35–1.65 0.92 1.00 14.2 24.8
TOP1/CEN-2 2.0 none 0.70 0.80 10 20
2.0 1.80–2.20 0.88 0.95 17.5 27.9
TOP1/CEN-20 1.5 none 0.82 0.87 10 20
1.5 1.35–1.65 0.96 0.99 17.1 27.8
TOP1/CEN-20 2.0 none 0.96 0.99 10 20
2.0 1.80–2.20 0.96 0.99 11 21.2
doi:10.1371/journal.pone.0060613.t006
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In the present study, higher CEN-2 counts were significantly
associated with longer survival in the multivariate analysis (HR:
0.38, 95% CI: 0.15–0.94, p = 0.04). This suggests longer survival
time for patients with tumors with a higher total number of
chromosomes, i.e. near-triploidy and -tetraploidy, which stands in
contrast to previously published results, which describe near-
triploid karyotypes being associated with shorter survival when
compared with near-diploid ones in CRC [38]. It should be noted
that CEN-20 aneusomy was detected to a lesser extent at higher
ploidy levels (see Table 2), opening the possibility that the
association between CEN-2 and survival may be attributed to this.
Alternatively, aneusomy of chromosome 2 (estimated to occur in
12.6% of specimens, detected in near-triploid and near-tetraploid
tumors) may contribute to an undocumented prognostic value of
chromosome 2 numeric aberrations. In any case, this result
requires further validation in another patient cohort.
It is unknown which types of TOP1 gene copy increase
mechanisms, if any, yield tumors responsive or resistant to Top1
inhibitor treatment, such as irinotecan. The present study has
several limitations, including a patient population treated with out-
dated surgical techniques and no adjuvant therapy and should
merely serve as an explorative study of the types of TOP1 gene
copy increases present in CRC and how these can be detected by
FISH. Predictive biomarkers often harbor a prognostic compo-
nent, a feature which may potentially overshadow the beneficial
effects of a given treatment unless the prognostic element has been
investigated [39]. While a limited number of significant relation-
ships were identified in this study, we believe that the findings are
relevant to report as they may aid future study design to determine
whether TOP1 gene aberrations hold any predictive value in
relation to TOP1 inhibitor-based chemotherapy. We observed
that TOP1 non-amplified gains showed a non-significant tendency
toward poorer prognosis, which may be attributed to increased
expression of other cancer-related genes on 20q (see section 4.2).
The prognostic value of amplification, which appeared to be
positive, could not be clearly determined due to the low number of
events. CEN-2 aneusomy occurred at levels lower than CEN-20,
suggesting that it is more suitable as a reference probe to detect
ploidy levels, as supported by the findings from the CRC
metaphase panel. As no deletions were observed (TOP1/CEN-
2,0.8), we can conclude that high level CEN-2 aneusomy does
not occur independently of CEN-20 gain. The significant
relationship between longer survival and higher CEN-2 counts
should be interpreted with caution, as only two samples were in
the tetraploid range and this relationship was not observed with
other clinical endpoints. We therefore propose that CEN-2 be
used in combination with other reference probes to elucidate the
mechanism of gene gain, which may have relevance in other
studies of copy number alterations by FISH. Future plans for
TOP1 FISH include testing both probe combinations in a
retrospective material with a suitable number of irinotecan treated
patients and relevant controls to determine whether any of the
TOP1 status subgroups respond to irinotecan. Furthermore, a
probe set including both centromere probes in different colors will
be considered to reduce observer workload.
4.5 Updated Guidelines
In order to reduce observer workload, the possibility of
determining TOP1 status by scoring fewer nuclei was investigated.
As shown in Table 6, using a borderline interval achieves
improved concordance when compared to scoring without using
a borderline interval. For the validation of a HER2 assay, Wolff
et al. [19] suggest a minimum of 95% concordance with an
alternative validated method or same validated method, a
requirement which was adopted in the current study. For
TOP1/CEN-2 (cut-off 1.5), this requirement was surpassed by
the inclusion of 20 nuclei with additional nuclei scored if the ratio
was within the relevant borderline interval after 20 nuclei. This
resulted in an average of 24.8 nuclei scored for each sample with
these updated guidelines. For TOP1/CEN-20 (cut-off 2.0), scoring
10 nuclei was sufficient to achieve a concordance of 0.96. For
practical purposes, we have chosen to score 20 nuclei with relevant
borderline intervals to determine TOP1 status, thereby reducing
the amount of scored nuclei by 58.7 and 64.7 percent for TOP1/
CEN-2 (cut-off 1.5) and TOP1/CEN-20 (cut-off 2.0), respectively
(see mean nuclei scored, Table 6). We therefore propose that
future use of TOP1 FISH in CRC is based upon scoring 20 nuclei
containing both gene- and reference signals and using the
aforementioned borderline intervals, where an additional 20
nuclei must be scored. TOP1 status could not be determined by
use of the TOP1 gene probe by itself in a reproducible manner
(data not shown).
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